Compared to patients with advanced cancer who were simply told about the likelihood of success with cardiopulmonary resuscitation (CPR), those who viewed a video of CPR were less likely to opt for its use.
Patients of lower socioeconomic status are less likely to be referred to participate in early-phase cancer trials compared with patients of higher socioeconomic status.
Survivors of cancers are more likely to report poor physical and mental health-related quality of life (HRQOL), compared with adults without cancer, with considerable variation noted for different types of cancers.
Definitional issues and non-acceptance of patients receiving chemotherapy are the barriers to earlier referral to specialized palliative care (SPC) by oncologists.
More intensive chemotherapy (every two weeks versus every three weeks) improves event-free survival for patients with localized Ewing sarcoma.
The age-adjusted disability-adjusted life-years (DALYs) lost from cancer are considerable, with 169.3 million years of healthy life lost globally in 2008.
In patients with giant-cell tumor of bone (GCTB), denosumab treatment causes a significant reduction in tumor giant cells and increased growth of new bone.
Bedford Laboratories announced the expansion of its previous nationwide recall of Leucovorin Calcium Injection.
For patients with rheumatoid arthritis (RA), the use of biologic response modifiers (BRMs) for at least six months is not associated with an increased risk of malignancy compared with placebo or other disease-modifying antirheumatic drugs (DMARDs).
Daily aspirin use is associated with lower overall cancer mortality, but the association may be smaller than previously reported.
